肝素酶基因表达与肺癌转移活性的初步研究

Expression of heparanase gene and the metastatic activity of lung cancer

目的 探讨肝素酶基因表达与肺癌转移的关系。方法 应用肝素酶基因引物、逆转录聚合酶链反应技术 (RT PCR)检测肺巨细胞癌株和 5 6例原发肺癌及正常肺组织中肝素酶基因表达。结果 低转移和高转移的肺巨细胞癌株均为肝素酶基因表达阳性 ;已有淋巴结转移的肺癌阳性率为 80 % (2 0 / 2 5 ) ,而无淋巴结转移的肺癌阳性率为 6 .5 % (2 / 31) ,两组间差异有显著性 (P <0 .0 0 1)。提示伴有淋巴结转移的病例肝素酶基因表达阳性率明显高于不伴转移者。肝素酶基因表达多见于鳞癌 (P <0 .0 5 )和低分化癌 (P <0 .0 1) ,亦提示肝素酶基因表达可能与组织学分型及分化程度有关。结论 初步结果显示肝素酶基因表达可能为肺癌细胞获得转移活性的可靠标志之一 ,其检测可用于辅助判断肺癌患者预后。

Objective To investigate the relationship between the expression of heparanase gene and the metastatic activity of lung cancer. Methods Using the primers of heparanase gene, the expression of heparanase gene was detected by reverse transcriptase polymerase chain reaction (RT PCR) in two giant cell lung cancer cell lines with different metastatic activity and 56 primary tumor tissues of lung cancer and normal lung tissues. Results Both cell lines and 80% (20/25) of primary tumor tissues of lung cancer with lymph node metastasis showed positive expression of heparanase gene, whereas 6.5% (2/31) primary tumor tissues of lung cancer without lymph node metastasis was positive and the normal lung tissues were all negative. The positive rate for expression of heparanase gene was significantly higher in the tumor tissues with lymph node metastasis than that without lymph node metastasis (P<0.001), higher in squamous cell carcinoma ( 47.2% , 17/36) than that in adenocarcinoma (20%, 4/20)(P<0.05), and remarkably higher in the poorly differentiated tumors (65%, 13/20) than that in the well mediate differentiated tumors (22.2%, 8/36)(P<0.01). Conclusion The preliminary results suggest that the expression of heparanase gene may be one of the reliable markers for the metastastic activity gained by the lung cancer cells and could be used clinically in predicting the prognosis of patients.